# US 2021/0330658 A1 · 5-ht2a agonists for use in treatment of depression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330658 A1
- Document ID: US20210330658A1
- Status: Published application
- Kind: A1
- Application number: 17/368,351
- Filed: 2021-07-06
- Published: 2021-10-28
- Earliest claimed: 2019-11-07
- Assignees: Lophora ApS
- Applicants: Lophora ApS
- Inventors: Jesper Langgaard KRISTENSEN; Anders Asbjørn JENSEN; Emil MÄRCHER-RØRSTED; Sebastian LETH-PETERSEN
- Web page: https://patentgrep.com/patent/US20210330658A1

## CPC

- A61K 31/452: Piperidinium derivatives (pancuronium A61K31/58)
- A61K 31/397: having four-membered rings, e.g. azetidine
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/451: having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A61P 25/24: Antidepressants
- C07D 205/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 207/08: with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D 211/22: by oxygen atoms
- C07D 211/34: with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to agonists of the 5-HT2A serotonin receptors and their medical uses. In one aspect the invention relates to 5-HT2A agonists of formula (I). In second aspect, the invention relates to selective 5-HT2A agonists of formula (II). In another aspect, the invention relates to mixed 5-HT2A/5-HT2C agonists of formula (III). In yet another aspect, the invention relates to 5-HT2A agonists for use in the treatment of a depressive disorder, more particular a 5-HT2A agonist for the use in the treatment of treatment-resistant depression.

## Claims

### Claim 1

A method of treating a disease, disorder, addiction or abuse comprising:
Administering an effective amount of a medicament comprising a compound of general formula (III) or a pharmaceutically acceptable salt thereof to a subject in need thereof;
Wherein general formula (III) has the structure, (III)
wherein:
X is selected from the group consisting of F, Cl, Br, I, CN, S—(C1-C5 alkyl), S—(C1-C5 fluoroalkyl), S—(C2-C5 alkenyl), S—(C2-C5 fluoroalkenyl), S—(C2-C5 alkynyl), S—(C2-C5 fluoroalkynyl), C1-C5 alkyl, C1-C5 fluoroalkyl, C2-C5 alkenyl, C2-C5 fluoroalkenyl, C2-C5 alkynyl, and C2-C5 fluoroalkynyl;
Y1 and Y2 are independently selected from the group consisting of H, O, S, C1-C3 alkyl, C1-C3 fluoroalkyl, and halogen;
R1 is not present when Y1 is H, C1-C3, alkyl, C1-C3 fluoroalkyl or halogen;
R2 is not present when Y2 is H, C1-C3, alkyl, C1-C3 fluoroalkyl or halogen;
when present, R1 and R2 are independently selected from the group consisting of C1-C5 alkyl, C1-C5 fluoroalkyl, C2-C5 alkenyl, C2-C5 fluoroalkenyl, C2-C5 alkynyl, C2-C5 fluoroalkynyl, C3-C5 cycloalkyl, and C3-C5 fluorocycloalkyl;
* denotes the (R) or (S) stereoisomer or any mixture thereof if a chiral center is present;
n is an integer with a value of 1 or 2 to form an azetidine or pyrrolidine ring system;
z denotes the number of R3 groups and is an integer with a value of 0, 1, 2, 3 or 4
each R3 is independently selected from the group consisting of F, C1-C3 alkyl, C1-C3 fluoroalkyl, C2-C3 alkenyl, and C2-C3 alkynyl;
R4 is H or CH3;
with the proviso that at least one of Y1 or Y2 is selected as O or S.

### Claim 2 (depends on 1)

A method according to claim 1, wherein X is selected from F, Cl, Br, I, CN, S—(C1-C3 alkyl), S—(C1-C3 fluoroalkyl), C1-C3 alkyl or C1-C3 fluoroalkyl; Y1 and Y2 are independently selected from O, CH3, or S; R1 and R2 are independently selected from not present (R1 not present if Y1 is CH3, R2 not present if Y2 is CH3), C1-C3 alkyl, C1-C3 fluoroalkyl, C3-C5 cycloalkyl; z is 0, 1, 2 or 3; and R3 is/are independently selected from F, C1-C2 alkyl or C1-C2 fluoroalkyl.

### Claim 3 (depends on 1)

A method according to claim 1, wherein X is selected from the group consisting of F, Cl, Br, I, CN, S—CH3, S—CF3, C1-C3 alkyl, C1-C3 fluoroalkyl, ethynyl, fluoroethynyl, and cyclopropyl; R1 and R2 are independently selected from the group consisting of C1-C3 alkyl, C1-C3 fluoroalkyl, and C3-C5 cycloalkyl; z is 0, 1 or 2; and each R3 is independently selected from the group consisting of F, C1-C2 alkyl, and C1-C2 fluoroalkyl.

### Claim 4 (depends on 1)

A method according to claim 1, wherein X is selected from the group consisting of F, Cl, Br, I, CN, S—(C1-C3 alkyl), S—(C1-C3 fluoroalkyl), C1-C5 alkyl or C1-C5 fluoroalkyl, most preferably X is CF3.

### Claim 5 (depends on 1)

A method according to claim 1, wherein X is selected from the group consisting of F, Cl, Br, I, CN, S—CH3, S—CF3, C1-C3 alkyl, and C1-C3 fluoroalkyl.

### Claim 6 (depends on 1)

A method according to claim 1, wherein X is CF3.

### Claim 7 (depends on 1)

A method according to claim 1, wherein Y1 and Y2 are independently selected from the group consisting of O, S, C1-C2 alkyl, and C1-C2 fluoroalkyl.

### Claim 8 (depends on 1)

A method according to claim 1, wherein Y1 and Y2 are independently selected from the group consisting of O, S, CH3, and CF3, preferably the group consisting of O and S.

### Claim 9 (depends on 1)

A method according to claim 1, wherein R1 and R2 are independently selected from the group consisting of C1-C3 alkyl, and C1-C3 fluoroalkyl and cyclopropyl.

### Claim 10 (depends on 1)

A method according to claim 1, wherein R1 and R2 are independently selected from the group consisting of C1-C3 alkyl, and C1-C3 fluoroalkyl; and wherein Y1 and Y2 are O.

### Claim 11 (depends on 1)

A method according to claim 1, wherein n is an integer with a value of 1 to form an azetidine.

### Claim 12 (depends on 1)

The method of claim 1, wherein the compound of general formula (III) or a pharmaceutically acceptable salt thereof is administered in order to treat a disease, disorder, addiction or abuse selected from a list consisting of major depressive disorder (MDD) (also known as clinical depression, unipolar depression), melancholia, psychotic depression, antenatal depression, postnatal depression, bipolar disorder, bipolar type I disorder, bipolar type II disorder, cyclothymic disorder, dysthymic disorder or seasonal affective disorder, treatment-resistant depression disorder (TRD), severe treatment-resistant depression disorder, Alzheimer's disease, Parkinson's disease, autism, general anxiety, existential anxiety, end of life anxiety, terminal cancer related end of life anxiety, epilepsy, sleep-wake disorders, neurocognitive disorders, obsessive compulsive disorder (OCD), attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), stress, acute stress disorder, Horton's headache, chronic cluster headache, migraine, general local inflammation, muscle inflammation, joint inflammation, pulmonary inflammation, asthma, arthritis, smoking cessation, alcohol cessation, cocaine cessation, heroin cessation, opioid cessation, methamphetamine cessation, general addiction therapy, eating disorders such as compulsive eating disorders, anorexia nervosa, bulimia nervosa, binge eating disorder, Pica, Rumination disorder, avoidant/restrictive food intake disorder, night eating syndrome, other specified feeding or eating disorder (OSFED), body dysmorphic disorder, purging disorder, pain, chronic pain disorders, sleep wake disorders and physical rehabilitation.

### Claim 13 (depends on 1)

The method of claim 1, wherein the compound of general formula (III) or a pharmaceutically acceptable salt thereof is administered in order to treat a depressive disorder selected from a list consisting of major depressive disorder (MDD) (also known as clinical depression, unipolar depression), melancholia, psychotic depression, antenatal depression, postnatal depression, bipolar disorder, bipolar type I disorder, bipolar type II disorder, cyclothymic disorder, dysthymic disorder or seasonal affective disorder, treatment-resistant depression disorder (TRD) and severe treatment-resistant depression disorder.
